Abstract
Almost 5% of women is affected by irsutism and about 55% of these subjects start complaining on some signs during the adolescence period in which a considerable anxiety is connected with the body image. After having excluded Cushing's syndrome, CAH late onset, ovarian and adrenal turnours, we treated six adolescents (mean age 16yr 1mo)affected by hirsutism (Hatch's score ≥ 10) with 100 mg/daily of spironolactone for 12 months (200 mg/daily with score > 20 or therapeutical unsuccess after 6 months of therapy). To all subjects was added an oral contraceptive (0.15 mg of descgestrel + 0.03 mg of ethinil -estradiol) to obtain regular withdrawal bleeding and contraception effect. To make a correct evaluation of the data, we excluded from the study those areas treated by esthetic treatment. Clinical and hormonal evaluations (FSH, LH, PRL, T, DHEAs) were obtained before and after 3-6-9-12 months of therapy. During follow-up no change was demonstrated in hormone levels; the mean score significantly decreased after 3 months of therapy (p < 0.01) and at every specific control (p < 0.001). In one girl, 6 months off-therapy, no sign of hirsutism was demonstrated. No significant side-effects were noted in our patients. Spironolactone combined to an cstro-progestagen is an effective and well-tolerated approach to the smanagement of hirsutism in adolescents.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Calzi, P., Gargantini, L., Nizzoli, G. et al. 126 SPITRONIACTONE OOMBINED TO AN ESTIRO-PROGESTAGEN IN ADOUESCENIS AFFECTED BY HIRSUTISM. Pediatr Res 24, 538 (1988). https://doi.org/10.1203/00006450-198810000-00147
Issue Date:
DOI: https://doi.org/10.1203/00006450-198810000-00147